Menu
At Inoviem Scientific, we share your goal: to fight diseases and address unmet medical needs. We support every stage of drug development—from target validation to clinical trials—using human pathological tissues and our established platforms working directly on patient tissues. Whether you’re developing small molecules or biologics for cancer, autoimmune, metabolic, or other diseases, we provide enabling information to unlock the full potential of your molecule with faster breakthroughs, lower risks, and a competitive edge.
Our established platforms use real human tissue data to reveal how your drug will perform in the organism, helping you validate targets, understand mechanisms of action, and identify predictive biomarkers—saving you time, money, and resources.
Traditional drug development models often fail to predict how a treatment will perform in humans. We change that by working directly with human tissues, providing results that reflect the real-world human response. This real patient-centric approach allows us to:
What our clients say
Our approach is based on the simple idea that current technologies fail to consider the natural environment in which a drug will have its beneficial effect. Due to concerns about the drug-target mode of action, the target is usually removed from its natural environment, resulting in the loss of important information and biasing the drug development process. The consequences of this are commercialized drugs with unexpected undesired effects or a loss of therapeutic efficacy.
Inoviem avoids this shortcoming by developing label-free technologies working directly on human tissue and using human samples as the analysis substrate; technology and physiology are therefore reconciled.
Ongoing investment in developing complementary technologies ensures that we remain at the forefront of innovation and bring the most creative and effective translational solutions to our clients.
News, events & resources
See more resources
